COVID-19: EU Assessing Booster Dose Of Pfizer/BioNTech’s Comirnaty
Inflammatory Syndrome Side-Effect Also Under Investigation
As the debate continues over whether booster vaccines will be required to sustain waning immune responses in the general population, the EU regulator says it should have the results of its assessment of an application for a booster dose of Cominarty in the next few weeks.
You may also be interested in...
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.
The EU’s pharmacovigilance committee has recommended safety updates for two COVID-19 vaccines, and is keeping its eye on a range of possible side-effects with all four authorized products.
Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.